+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma



Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma



Experimental and Molecular Pathology 100(1): 236-241



To evaluate the clinical value of immunohistochemistry (IHC) using anti-BRAF V600E antibody (clone VE1) for specific detection of the BRAF V600E mutant protein in formalin-fixed paraffin-embedded papillary thyroid carcinoma (PTC) specimens. A total of 118 PTC cases and 116 control cases processed between January 2008 and June 2010 were selected and created tissue microarrays (TMAs) for the study. BRAF V600E (VE1) IHC was performed on tissue sections from PTC cases to determine mutation status. Molecular tests (Sanger sequencing/ARMS) were used to confirm the BRAF V600E gene mutation in primary PTC. A uniformly cytoplasmic staining throughout the tumors was observed in IHC-positive cases. BRAF V600E was detected in 68.6% (81/118) of PTC samples by IHC and in 61.9% (73/118) by Sanger sequencing/ARMS. The overall concordance between IHC and Sanger sequencing/ARMS was 93.2% (110/118). The sensitivity and specificity of the BRAF V600E IHC was 100% (73/73) and 82.2% (37/45), respectively. Positive and negative predictive values were 90.1% (73/81) and 100% (37/37), respectively. Expression of the BRAF V600E mutant protein was detected in all of 59 cases of primary carcinoma and corresponding metastatic carcinoma in lymph nodes. The concordance between IHC staining in primary and metastatic PTC was 100% (59/59). IHC using VE1 antibody for detection of the BRAF V600E mutant protein expression in PTC showed high sensitivity and acceptable specificity, which are critical for diagnostic purposes. IHC staining for BRAF V600E showed uniformly cytoplasmic expression in both primary tumor and metastatic nodes. Therefore, IHC has high practical value for the detection of the BRAF V600E mutation in metastatic and primary PTC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058886115

Download citation: RISBibTeXText

PMID: 26795218

DOI: 10.1016/j.yexmp.2016.01.004


Related references

Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction. Endocrinologia Diabetes Y Nutricion 64(2): 75-81, 2017

Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Head and Neck 32(1): 38-45, 2010

Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. Journal of Clinical Pathology 60(11): 1211-1215, 2007

Prevalence of BRAF V600E Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF V600E Prevalent Area. Journal of Korean Medical Science 33(27): E75, 2018

Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. American Journal of Surgical Pathology 36(6): 844-850, 2012

The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. Pathology 45(7): 637-644, 2013

Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery 154(6): 1199-204; Discussion 1204-5, 2013

Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma. Histopathology 69(3): 524-526, 2016

Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. International Journal of Clinical and Experimental Pathology 8(11): 15072-8, 2015

VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Virchows Archiv 467(2): 155-168, 2015

Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid carcinoma using multiplex allele-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography. Genetics and Molecular Research 12(4): 4990-4997, 2013

Conventional Ultrasound, Immunohistochemical Factors and BRAF V600E Mutation in Predicting Central Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma. Ultrasound in Medicine and Biology 44(11): 2296-2306, 2018

BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens. Annales de Pathologie 30(4): 252-262, 2010

A Case of Multifocal Papillary Thyroid Carcinoma Consisting of One Encapsulated Follicular Variant with BRAF K601E Mutation and Three Conventional Types with BRAF V600E Mutation. Korean Journal of Pathology 47(3): 293-298, 2013

Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Human Pathology 44(11): 2563-2570, 2013